SOMERSET, N.J., Aug. 13 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company’s product development programs at noon EDT on Aug. 20, 2007, at the Noble Financial Two Double-0-Seven Conference at the Charleston Place Hotel in Charleston, S.C.
The audio and slide presentation will be available on Alfacell’s Web site www.alfacell.com and Noble Financial’s conference Web site at www.two-007.net. A replay will be available at these addresses immediately after the live presentation and will be archived for 90 days.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact: Investor Contact: David Schull or Wendy Lau Andreas Marathovouniotis Russo Partners Russo Partners 212-845-4271 212-845-4253 david.schull@russopartnersllc.comandreas.marathis@russopartnersllc.comwendy.lau@russopartnersllc.com
Alfacell Corporation
CONTACT: Media, David Schull, david.schull@russopartnersllc.com, or WendyLau, wendy.lau@russopartnersllc.com, +1-212-845-4271, or Investors, AndreasMarathovouniotis, +1-212-845-4253, orandreas.marathis@russopartnersllc.com, all of Russo Partners
